GoldenGolden
Advanced Search
Vaxil Bio Therapeutics

Vaxil Bio Therapeutics

A biotechnology company focused on cancer immunotherapy. It was founded in 2007 and is based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL

Vaxil Bio Therapeutics is an Israel-based immuno-oncology biotechnology company specializing in cancer and infectious diseases. It conducts research and development of medical solutions for its studied illnesses. Its lead product, IMMUCIN, is for immunotherapy purposes and has been given orphan drug status from both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

COVID-19

In 2020, the company utilized its VaxHit bioinformatics platform to create a vaccine candidate for COVID-19 using signal peptide technology. The candidate's design has been successful in testing a tuberculosis vaccine.

Timeline

People

Name
Role
LinkedIn

David Goren

Further reading

Title
Author
Link
Type
Date

Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing

Vaxil Bio Ltd.

Web

February 13, 2020

Vaxil Bio : COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT | MarketScreener

MarketScreener

Web

March 27, 2020

Documentaries, videos and podcasts

Title
Date
Link

VAXIL Introduction - Cancer Immunotherapy

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.